Vident Advisory LLC Has $4.63 Million Holdings in Lantheus Holdings, Inc. $LNTH

Key Points

• Vident Advisory LLC significantly increased its stake in Lantheus Holdings, Inc. by 1,610.9%, acquiring a total of 47,427 shares, valued at approximately $4.6 million.
• Insider Rajiv A. Patel sold 3.36 million shares of Lantheus stock for around $189 million, representing a 49.18% decrease in his holdings.
• Analysts have mixed ratings for Lantheus, with an average target price of $105.50 and ratings ranging from "buy" to "hold".

Vident Advisory LLC grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 1,610.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 47,427 shares of the medical equipment provider's stock after buying an additional 44,655 shares during the quarter. Vident Advisory LLC owned 0.07% of Lantheus worth $4,629,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Lantheus by 3.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider's stock worth $1,162,000 after purchasing an additional 400 shares in the last quarter. State of Alaska Department of Revenue increased its position in shares of Lantheus by 2.7% during the 1st quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider's stock worth $794,000 after purchasing an additional 215 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Lantheus by 12,517.1% during the 1st quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider's stock worth $12,536,000 after purchasing an additional 127,424 shares in the last quarter. Cerity Partners LLC increased its position in shares of Lantheus by 12.7% during the 1st quarter. Cerity Partners LLC now owns 11,709 shares of the medical equipment provider's stock worth $1,143,000 after purchasing an additional 1,323 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Lantheus by 1,196.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider's stock worth $32,817,000 after purchasing an additional 310,301 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on LNTH. B. Riley dropped their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research report on Monday, June 23rd. JMP Securities dropped their target price on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research report on Thursday, August 7th. Truist Financial set a $63.00 target price on shares of Lantheus and gave the stock a "hold" rating in a research report on Monday, August 11th. William Blair restated a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. Finally, Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Lantheus has a consensus rating of "Moderate Buy" and a consensus price target of $91.60.

Insider Buying and Selling at Lantheus

In related news, insider Rajiv A. Patel sold 3,365,000 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider directly owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares in the company, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,812,000 shares of company stock worth $382,427,380 over the last ninety days. 1.50% of the stock is currently owned by insiders.

Lantheus Trading Up 2.3%

Lantheus stock traded up $1.24 during midday trading on Friday, hitting $55.06. 336,508 shares of the stock were exchanged, compared to its average volume of 1,198,991. The company has a fifty day simple moving average of $67.12 and a two-hundred day simple moving average of $82.46. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $118.21. The stock has a market capitalization of $3.74 billion, a PE ratio of 14.65 and a beta of 0.15. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.08). The firm had revenue of $378.05 million for the quarter, compared to the consensus estimate of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm's revenue was down 4.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.80 EPS. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.